Pomeranian Medical University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Szczecin Poland (1948)

Organization Overview

First Clinical Trial
2007
NCT00831337
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Department of Functional Diagnostics and Physical Medicine, PUM | Department of General Pathology, Pomeranian Medical University in Szczecin, Poland | Department of Neonatology, Pomeranian Medical University in Szczecin, Poland | Department of Neurology, Pomeranian Medical University, Szczecin, Poland | Pomenarian Medical University | Pomeranian Medical Univerisity | Pomeranian Medical Universitet Szczecin | Pomeranian Medical University | Pomeranian Medical University in Sczecin | Pomeranian Medical University Szczecin

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Anemia, Neonatal (Phase 1)

Arthralgia (Phase 2)

Atrial Fibrillation (Phase 4)

Breast Neoplasms (Phase 2)

Bronchopulmonary Dysplasia (Phase 1)

Enterocolitis (Phase 1)

Enterocolitis, Necrotizing (Phase 1)

Fibrosis (Phase 4)

Hemorrhage (Phase 1)

Intracranial Hemorrhages (Phase 1)

Joint Diseases (Phase 2)

Liver Cirrhosis (Phase 4)

Liver Cirrhosis, Biliary (Phase 4)

Macular Degeneration (Phase 1)

Premature Birth (Phase 1)

Respiratory Distress Syndrome (Phase 1)

Respiratory Distress Syndrome, Newborn (Phase 1)

Retinal Degeneration (Phase 1)

Retinal Diseases (Phase 1)

Retinitis (Phase 1)

Retinitis Pigmentosa (Phase 1)

Retinopathy of Prematurity (Phase 1)

Syndrome (Phase 4)

Temporomandibular Joint Disorders (Phase 2)

Temporomandibular Joint Dysfunction Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 29